Business Context and Reporting Period
This Form 8-K Current Report was filed by Revolution Medicines, Inc. on June 8, 2022, covering events occurring on June 8 and June 10, 2022. The filing addresses Item 5.02 regarding the amendment of the employment agreement for Mark Goldsmith, M.D., Ph.D., the Company's President and Chief Executive Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation arrangements and does not contain financial performance data.
Material Changes
The primary material change reported is the amendment to Dr. Goldsmith's employment agreement, approved by the Compensation Committee on June 8, 2022, and executed on June 10, 2022. The amendment increases the severance package payable to Dr. Goldsmith in the event of termination without Cause or resignation for Good Reason during a specific window surrounding a change in control (from three months prior to 18 months following).
- Previous Severance Multiplier: 1.5x the sum of annual base salary and target annual bonus.
- New Severance Multiplier: 2x the sum of annual base salary and target annual bonus.
Guidance, Outlook, and Risks
The filing does not contain guidance, outlook, or general management commentary regarding the Company's business strategy or financial future. The only risk or contingency noted is the specific condition triggering the increased severance payment: a change in control occurring within the defined 21-month window relative to the termination event.
Investor Verification Checklist
- Verify the exact terms of "Cause" and "Good Reason" as defined in the original Goldsmith Employment Agreement to understand the scope of the severance trigger.
- Review the full text of the Goldsmith Amendment (Exhibit 10.1) for any additional clauses or conditions not summarized in the 8-K.
- Confirm the current annual base salary and target annual bonus for Dr. Goldsmith to calculate the potential financial impact of the increased multiplier.
- Assess the Company's current status regarding any potential change in control transactions that might activate this provision.